{{Chembox
| ImageFile = Etomoxir.svg
| ImageSize = 200px
| ImageAlt = 
| IUPACName = Ethyl 2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate
| OtherNames = 
| Section1 = {{Chembox Identifiers
| CASNo = 828934-41-4
| ChEMBL = 2051959
|  PubChem = 9840324
|  ChemSpiderID = 8016042
|  SMILES = CCOC(=O)[C@]1(CO1)CCCCCCOC2=CC=C(C=C2)Cl
|  InChI = 1/C17H23ClO4/c1-2-20-16(19)17(13-22-17)11-5-3-4-6-12-21-15-9-7-14(18)8-10-15/h7-10H,2-6,11-13H2,1H3/t17-/m1/s1
|  InChIKey = DZLOHEOHWICNIL-QGZVFWFLBM
|  StdInChI = 1S/C17H23ClO4/c1-2-20-16(19)17(13-22-17)11-5-3-4-6-12-21-15-9-7-14(18)8-10-15/h7-10H,2-6,11-13H2,1H3/t17-/m1/s1
|  StdInChIKey = DZLOHEOHWICNIL-QGZVFWFLSA-N

  }}
| Section2 = {{Chembox Properties
| C=17|H=23|Cl=1|O=4
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility = 
  }}
| Section3 = {{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
  }}
}}
'''Etomoxir''', or '''2[6(4-chlorophenoxy)hexyl]oxirane-2-carboxylate''', is an irreversible inhibitor of [[carnitine palmitoyltransferase-1]] (CPT-1) on the outer face of the [[inner mitochondrial membrane]].<ref>{{Cite journal
 |author1=Y. T. Kruszynska |author2=H. S. Sherratt |title = Glucose kinetics during acute and chronic treatment of rats with 2&#91;6(4-chloro-phenoxy)hexyl&#93;oxirane-2-carboxylate, etomoxir|journal = [[Biochemical Pharmacology (journal)|Biochemical pharmacology]]|volume = 36|issue = 22|pages = 3917–3921|date=November 1987|pmid = 3689429|doi=10.1016/0006-2952(87)90458-8}}</ref> This prevents the formation of acyl carnitines, a step that is necessary for the transport of fatty acyl chains from the [[cytosol]] into the intermembrane space of the [[mitochondria]]. This step is essential to the production of [[Adenosine triphosphate|ATP]] from [[fatty acid oxidation]]. Etomoxir has also been identified as a direct agonist of [[PPARα]].<ref>{{Cite web|url = https://www.caymanchem.com/app/template/Product.vm/catalog/11969;jsessionid=30AE614E0FF39230A892546160E7112A|title = (+)-Etomoxir (sodium salt)|date = 2015|accessdate = 18 March 2015|website = Cayman Chemical|publisher = Cayman Chemical Company}}</ref>

A [[double-blind]] [[crossover study]] in human adult males showed that treatment with etomoxir enhanced feelings of hunger and increased meal portion size by 22%.<ref name="pmid10575655">{{cite journal|vauthors=Kahler A, Zimmermann M, Langhans W | title=Suppression of hepatic fatty acid oxidation and food intake in men. | journal=Nutrition | year= 1999 | volume= 15 | issue= 11-12 | pages= 819–28 | pmid=10575655 | doi= 10.1016/s0899-9007(99)00212-9| pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10575655  }}</ref>

Etomoxir has been reported to decrease the incorporation of [[palmitic acid]] and [[oleic acid]] into [[cardiolipin]], although it does not affect the activities of cardiolipin biosynthesis and remodeling.<ref name="pmid12576524">{{cite journal |vauthors=Xu FY, Taylor WA, Hurd JA, Hatch GM |title=Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells |journal=J. Lipid Res. |volume=44 |issue=2 |pages=415–23 |year=2003 |pmid=12576524 |doi=10.1194/jlr.M200335-JLR200 |url=http://www.jlr.org/cgi/pmidlookup?view=long&pmid=12576524 |accessdate=2015-03-17}}</ref>

== Licensing and clinical development ==
Etomoxir has already been through [[Phases of clinical research|phase II clinical development]] for the treatment of [[type 2 diabetes]] and [[heart failure]]. Etomoxir went through [[preclinical trial]]s by Byk Gulden laboratories (now [[Altana|Altana Pharma AG]]) from 1981 to 1984.<ref name=":0">{{Cite web|url = http://www.bioscience-beteiligungs-anstalt.com/en/|title = Drug candidates with blockbuster potential|date = 2015|accessdate = 19 March 2015|website = bioscience-beteiligungs-anstalt.com|publisher = BioScience Beteiligungs Anstalt}}</ref> From 1984 to 1993, etomoxir was developed through phase I and II trials that showed favorable effects on the heart and a good safety profile.<ref>{{Cite web|url = http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=10102|title = MediGene AG starts phase 2 clinical trial for its cardiac lead product Etomoxir|date = 12 December 2000|accessdate = 19 March 2015|website = Evaluate|publisher = Evaluate Ltd}}</ref> In 1999, the [[patent]] was out-licensed to [[MediGene]] for further trials.<ref name=":0" /> In 2001, MediGene was granted extended patent rights for the use of etomoxir for the treatment of [[congestive heart failure]].<ref>{{Cite web|url = http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=10110|title = MediGene´s rights for Etomoxir extended to novel indications|date = 15 February 2001|accessdate = 19 March 2015|website = Evaluate Group|publisher = Evaluate Ltd}}</ref> In 2002, MediGene announced that it terminated a phase II trial for the use of etomoxir for heart failure due to adverse [[side effects]].<ref>{{Cite web|url = http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=24873|title = MediGene’s Etomoxir project delayed|date = 19 April 2002|accessdate = 19 March 2015|website = Evaluate Group|publisher = Evaluate Ltd}}</ref> MediGene funded a study of etomoxir as a treatment of heart failure in 2007, but the study was once again terminated prematurely. Four of the 226 patients taking the drug showed unacceptably high liver [[transaminase]] levels, which was determined by the experimenters to likely be due to the treatment.<ref name="pmid17319797">{{cite journal|vauthors=Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P | title=A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. | journal=Clin Sci (Lond) | year= 2007 | volume= 113 | issue= 4 | pages= 205–12 | pmid=17319797 | doi=10.1042/CS20060307 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17319797  |display-authors=etal}}</ref> The [[University of Colorado]] currently holds patents for the use of etomoxir as an [[anti-inflammatory]] and [[anticarcinogenic]] agent.<ref>Newell, Martha K., Evan Newell, and Elizabeth Villobos-Menvey. [http://www.google.com/patents/US7510710 Etomoxir and a 2-deoxy-D-glucose Compound; Antiinflammatory, Antiproliferative, Anticarcinogenic and Wound Healing Agents; Drug Resistant Cancers]. The Regents Of The University Of Colorado, assignee. Patent US7510710 B2. 31 Mar. 2009.</ref> However, the clinical development of etomoxir has been terminated due to severe [[hepatotoxicity]] associated with treatment.<ref name="pmid24113830">{{cite journal|vauthors=Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G | title=Metabolic targets for cancer therapy. | journal=Nat Rev Drug Discov | year= 2013 | volume= 12 | issue= 11 | pages= 829–46 | pmid=24113830 | doi=10.1038/nrd4145 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24113830  }}</ref>

==References==
{{Reflist|2}}


{{PPAR modulators}}

[[Category:Epoxides]]
[[Category:Ethyl esters]]
[[Category:Chloroarenes]]
[[Category:Phenol ethers]]
[[Category:Enzyme inhibitors]]